false
0000749647
0000749647
2023-12-07
2023-12-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 7, 2023
IMUNON,
INC.
(Exact
name of registrant as specified in its Charter)
Delaware |
|
001-15911 |
|
52-1256615 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
997
Lenox Drive, Suite 100, Lawrenceville, NJ |
|
08648-2311 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(609)
896-9100
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.01 per share |
|
IMNN |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On
December 7, 2023, Imunon, Inc. (the “Company”) appointed Dr. Sébastien Hazard to the positions of Executive Vice President
and Chief Medical Officer of the Company, effective as of December 11, 2023.
Dr.
Hazard (age 52) served as Head of Clinical Development at Bicycle Therapeutics, Inc. from April 2021 through September 2023. Prior to
joining Bicycle Therapeutics, Inc., Dr. Hazard served as Clinical Development Lead at GSK from June 2019 to April 2021. He also served
as Senior Medical Director of Clinical Development from July 2018 to May 2019, and Senior Medical Director of Global Medical Affairs
from August 2016 to July 2018 at TESARO, Inc. Dr. Hazard held various positions within Genentech, including Medical Director in Lung
Cancer of U.S. Medical Affairs from November 2012 to July 2016. Dr. Hazard received a Doctorate in Medicine, Internal Medicine and Public
Health from Paris VI Pitie Salpetriere, an Executive M.B.A. from INSEAD and a Master’s degree in epidemiology and statistics applied
to clinical research from Paris VI University.
There
is no family relationship between Dr. Hazard and any other director or executive officer of the Company. There are no transactions between
the Company and Dr. Hazard disclosable pursuant to Item 404(a) of Regulation S-K.
In
connection with his appointment as Executive Vice President and Chief Medical Officer, Dr. Hazard entered into an offer letter of employment
with the Company, with his employment to be effective as of December 11, 2023. Pursuant to the offer letter, the Company will pay Dr.
Hazard an initial salary of $475,000 and a targeted annual performance bonus of 50% of his annual base salary. Dr. Hazard will also receive
(i) an option to purchase 80,000 shares of the Company’s common stock that will vest with respect to 25% of the subject shares
on December 11, 2024 and the remaining 75% will vest in equal quarterly installments thereafter such that the stock option will be fully
vested and exercisable as of the fourth anniversary of December 11, 2023, and (ii) a restricted stock award of 20,000 restricted shares
that will vest on December 11, 2024, in each case subject to Dr. Hazard’s continued service to the Company on the applicable vesting
dates. Dr. Hazard’s employment is “at will” and has no set term.
The
stock options and restricted shares will be granted outside the Company’s 2018 Stock Incentive Plan, as an inducement material
to Dr. Hazard’s entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The
foregoing description of the offer letter does not purport to be complete and is qualified in its entirety by the full text of the offer
letter, a copy of which is attached to this Current Report on Form 8-K as exhibit 10.1.
Item
7.01 |
Regulation
FD Disclosure |
A
copy of the Company’s press release announcing Dr. Hazard’s appointment as Executive Vice President and Chief Medical Officer
and announcing the inducement grants is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such a filing.
Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
IMUNON,
INC. |
|
|
|
Dated:
December 11, 2023 |
By: |
/s/
Jeffrey W. Church |
|
|
Jeffrey
W. Church |
|
|
Executive
Vice President, Chief Financial Officer and Corporate Secretary |
Exhibit
10.1
December
7, 2023
Dr.
Sébastien Hazard
7
Rangeley Rd.
Winchester,
MA 01890
hazardsebastien@gmail.com
Dear
Sébastien,
I
am pleased to extend to you an offer of employment with IMUNON, Inc. as Executive Vice President and Chief Medical Officer. In this capacity,
you will be a member of IMUNON’s senior executive staff and will report directly to me. Your starting salary will be $18,269.23
every two weeks, which is $475,000 on an annualized basis.
Additionally:
● |
You will be eligible for an annual bonus, with a target of 50% of your annual base salary, contingent upon meeting personal goals
and company objectives. |
|
|
● |
Your base salary will be subject to a performance review annually. |
|
|
● |
Subject to Board of Directors’ approval, you will be granted an inducement option to purchase 80,000 shares of IMUNON common
stock. Your Option Grant will vest in equal quarters over four years with the first quarter vesting on the one-year anniversary of
your first day of employment. Options will be exercisable at the closing price of our stock on the date of Board approval. |
|
|
● |
Subject to Board of Directors approval, you will also receive a restricted inducement stock grant in the amount of 20,000 shares
of IMUNON common stock. Your Stock Grant will vest on the one-year anniversary of your first day of employment. |
|
|
● |
In the event of the involuntary termination of your employment, for any reason other than for Cause, or in the event of your resignation
for Good Reason, IMUNON will provide you with a monthly salary continuation and health insurance premium payments for up to nine
(9) months. These benefits will cease if you find new employment prior to the end of the specified period. Salary continuation will
be subject to your execution of a mutually agreed General Release. |
This
offer is contingent on: (i) satisfactory discussions with your references; (ii) satisfactory pre-employment physical release from your
physician and passing a customary drug screen; and (iii) termination of any current consulting or employment engagements and your agreement
not to engage in consulting while an employee of IMUNON.
Your
salary will be paid bi-weekly in arrears. Salary payments will be automatically deposited into a checking/savings account of your choosing.
As
a member of our professional staff, your position is salaried and exempt from federal wage-hour law. You will not be eligible for overtime
pay for hours actually worked in excess of 40 in a given workweek. Your employment is at will. You or IMUNON may terminate our employment
relationship at any time with or without cause or notice. As such, neither this letter nor any other oral or written representations
may be considered a contract for any specific period of time.
Your
first 120 days of employment will be considered an introductory period. As such, I encourage you to discuss job performance, duties,
responsibilities and goals with me at any time; however, we will formally discuss your performance at the end of your first 120 days
with the Company.
You
will be eligible for a benefits package including medical, dental, life insurance, short and long-term disability and participation in
our 401(k) Plan. The Plan includes a company contribution of IMUNON stock, in kind, for 50% of the first 6% contribution made by you.
The Company will provide you with the opportunity to join our employee medical and dental insurance programs. Medical, dental and life
insurance coverage will be effective on the first day of the month following your employment date.
Your
annual vacation allowance is five (5) weeks per year, accrued per pay period, your vacation allowance for 2023 will be at a pro rata
percentage of a full year calculated from your first day of employment. In addition, you are eligible for holiday, sick and personal
days. Personal day allowance for 2023 has restrictions as specified in our Employee Handbook. Details of the entire benefits package
will be given to you on your first day of employment.
Please
sign and return this letter, by e-mail (clegoff@imunon.com), to indicate your acceptance of this position.
We
mutually agree that your start date will be December 11, 2023. On your first day of employment, please bring documentation for the purpose
of completing the I-9 Form which authorizes your employment in the United States.
If
you have any questions about the contents of this letter or about your employment with IMUNON, please contact me at 609-482-2454 or 310-924-0135
(cell).
On
behalf of the Management and Employees of IMUNON, I sincerely welcome you and wish to express our excitement with your decision to join
IMUNON, Inc.
Sincerely, |
|
|
|
|
|
/s/
Corinne Le Goff |
|
|
|
|
|
Corinne
Le Goff |
|
|
CEO
and President |
|
|
ACCEPTED: |
|
|
|
|
|
|
|
/s/
Sebastien Hazard |
|
12/7/2023 |
|
Dr.
Sébastien Hazard |
|
Date |
|
Exhibit
99.1
IMUNON
Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Accomplished
pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases
LAWRENCEVILLE,
N.J. (December 11, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral
DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer,
effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations,
most recently at Bicycle Therapeutics. He will report to IMUNON’s President and Chief Executive Officer, Dr. Corinne Le Goff.
“We
are delighted to welcome Dr. Hazard to IMUNON to lead this important function,” said Dr. Le Goff. “The timing is right to
add a CMO to advance the clinical development of our lead programs, in particular as we prepare to report topline data in the second
quarter of 2024 from the OVATION 2 Study with IMNN-001, our gene-mediated IL-2 immunotherapy based on our TheraPlas® platform, in
advanced ovarian cancer. Sebastien will be instrumental in supporting and crafting our go-forward strategy for this drug, in particular
because of his extensive oncology experience including ovarian cancer.”
Dr.
Hazard has nearly 25 years of experience in drug development and commercialization. Most recently he was Senior Vice President, Head
of Clinical Development at Bicycle Therapeutics, where he was instrumental in bringing the company’s lead asset from early to late-stage
clinical development. Prior to joining Bicycle, Dr. Hazard was with GSK as Clinical Development Lead, where he helped develop the PARP
inhibitor niraparib across multiple tumor types. Prior to joining GSK, he was Senior Medical Director at TESARO, which was subsequently
acquired by GSK, working to develop niraparib as a first-line treatment for ovarian cancer. In addition to holding various positions
at Genentech, F. Hoffmann-La Roche, Roche and Novartis, earlier in his career Dr. Hazard served as an advisor to the head of the French
Drug Agency and to the French Health Minister’s cabinet.
Dr.
Hazard holds a Doctorate in Medicine, Internal Medicine and Public Health from Paris VI Pitie Salpetriere, an Executive MBA from INSEAD
and a Master’s degree in epidemiology and statistics applied to clinical research from Paris VI University.
The
Company also announced today that on December 7, 2023, in connection with Dr. Hazard’s appointment as CMO, the Compensation Committee
of the Board of Directors of the Company approved an inducement option to purchase 80,000 shares of common stock (the “Inducement
Option”) and a restricted inducement stock grant of 20,000 shares of common stock (the “Restricted Inducement Grant”)
to Dr. Hazard. The Inducement Option has an exercise price of $0.88 per share, which is equal to the closing price of the Company’s
common stock on the Nasdaq Capital Market on December 7, 2023, will vest over four years, subject to Dr. Hazard’s continued service
with the Company on each applicable vesting date, with 25% of the underlying shares vesting on the one-year anniversary of the vesting
commencement date, and 75% of the underlying shares vesting in equal installments over the next twelve calendar quarters. The Restricted
Inducement Grant will vest on the one-year anniversary of Dr. Hazard’s first day of employment, subject to Dr. Hazard’s continued
service with the Company on such date. Each of the Inducement Option and the Restricted Inducement Grant is an inducement material to
Dr. Hazard entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About
IMUNON
IMUNON
is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the
body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting
a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across four modalities. The
first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where
an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens
that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in
infectious diseases. The third modality, FixPlas®, concerns the application of our DNA technology to produce universal
cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas®, is in the discovery
phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines.
The
Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer
currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting
molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical
studies for the development of a COVID-19 booster vaccine (IMNN-101) and a treatment for the LASSA virus (IMNN-102). The Company has
also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). We will continue to
leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.
For more information on IMUNON, visit www.imunon.com.
Forward-Looking
Statements
IMUNON
wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical
trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks
detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation to update
or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
#
# #
v3.23.3
Cover
|
Dec. 07, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 07, 2023
|
Entity File Number |
001-15911
|
Entity Registrant Name |
IMUNON,
INC.
|
Entity Central Index Key |
0000749647
|
Entity Tax Identification Number |
52-1256615
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
997
Lenox Drive
|
Entity Address, Address Line Two |
Suite 100
|
Entity Address, City or Town |
Lawrenceville
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
08648-2311
|
City Area Code |
(609)
|
Local Phone Number |
896-9100
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
stock, par value $0.01 per share
|
Trading Symbol |
IMNN
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024